CO5160289A1 - Composicion farmaceutica que inhibe o detiene el crecimiento de viruses, en animales, particularmente mamiferos util para tratar infecciones virales - Google Patents

Composicion farmaceutica que inhibe o detiene el crecimiento de viruses, en animales, particularmente mamiferos util para tratar infecciones virales

Info

Publication number
CO5160289A1
CO5160289A1 CO00023485A CO00023485A CO5160289A1 CO 5160289 A1 CO5160289 A1 CO 5160289A1 CO 00023485 A CO00023485 A CO 00023485A CO 00023485 A CO00023485 A CO 00023485A CO 5160289 A1 CO5160289 A1 CO 5160289A1
Authority
CO
Colombia
Prior art keywords
hydrogen
useful
group
pharmaceutical composition
viral infections
Prior art date
Application number
CO00023485A
Other languages
English (en)
Inventor
Camden James Berger
Joseph Herman Gardner
David Thomas Stanton
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5160289A1 publication Critical patent/CO5160289A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende una cantidad segura y eficaz de un éster de ácido carbámico que tiene la fórmula:<EMI FILE="00023485_1" ID="1" IMF=JPEG >en donde X independientemente es oxigeno o azufre, R se selecciona del grupo que consiste de hidrógeno y aIquilo que tiene de 1 a 4 átomos de carbono, R1 se selecciona del grupo que consiste de hidrógeno y alquilo que tiene de 1 a 4 átomos de carbono, en donde R2 independientemente se selecciona del grupo que consiste de hidrógeno y alquilo que tiene de 1 a 4 átomos de carbono, y en donde Y se selecciona del grupo que consiste de hidrógeno, cloro, fluoro, bromo, hidroxi, oxicloro y sulfhidrilo o sales de adición farmacéuticas o un derivado enlazado covalentemente, disociable de ésta en donde el éster de ácido carbámico antes mencionado es útil para tratar infecciones virales.
CO00023485A 1999-03-31 2000-03-31 Composicion farmaceutica que inhibe o detiene el crecimiento de viruses, en animales, particularmente mamiferos util para tratar infecciones virales CO5160289A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28189399A 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
CO5160289A1 true CO5160289A1 (es) 2002-05-30

Family

ID=23079212

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00023485A CO5160289A1 (es) 1999-03-31 2000-03-31 Composicion farmaceutica que inhibe o detiene el crecimiento de viruses, en animales, particularmente mamiferos util para tratar infecciones virales

Country Status (10)

Country Link
US (1) US6225307B1 (es)
EP (1) EP1169041A2 (es)
JP (1) JP2002540149A (es)
AR (1) AR018707A1 (es)
AU (1) AU764265B2 (es)
CA (1) CA2368647A1 (es)
CO (1) CO5160289A1 (es)
NZ (1) NZ514560A (es)
PE (1) PE20001610A1 (es)
WO (1) WO2000057868A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR626001A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A method of treatment and/or prophylaxis
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
JP2005060362A (ja) * 2003-07-28 2005-03-10 Shionogi & Co Ltd セスキテルペン誘導体を含有する抗HIV剤、抗BVDV剤、抗HCV剤又は抗CoV剤
US20050043253A1 (en) * 2003-08-19 2005-02-24 Cook Bradley R. Use of wound healing compositions for prevention of infections and allergies
CN110818633A (zh) 2009-01-16 2020-02-21 埃克塞里艾克西斯公司 一种苹果酸盐及其晶型

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2056439B (en) 1979-07-18 1983-03-09 Wyeth John & Brother Ltd Hexahydroazepine derivatives
EP0084920B1 (en) * 1979-12-05 1989-04-19 Per Arvid Emil Carlsson New compounds useful as intermediates or starting materials for preparation of therapeutically useful phenyl-azacycloalkanes
SE8305362D0 (sv) * 1983-09-30 1983-09-30 Astra Laekemedel Ab Novel substituted phenylazacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5114951A (en) 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
SK138397A3 (en) * 1995-04-12 1998-05-06 Procter & Gamble A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancer
WO1998045271A1 (en) 1997-04-10 1998-10-15 F. Hoffman-La Roche Ag Process for making a butylthio-isoquinoline and intermediates therefor

Also Published As

Publication number Publication date
AU764265B2 (en) 2003-08-14
AU4048600A (en) 2000-10-16
PE20001610A1 (es) 2001-02-09
WO2000057868A3 (en) 2001-01-11
EP1169041A2 (en) 2002-01-09
NZ514560A (en) 2004-02-27
AR018707A1 (es) 2001-11-28
WO2000057868A2 (en) 2000-10-05
CA2368647A1 (en) 2000-10-05
JP2002540149A (ja) 2002-11-26
US6225307B1 (en) 2001-05-01

Similar Documents

Publication Publication Date Title
PE13196A1 (es) Composiciones topicas acuosas
DE60306781D1 (de) Naturstoffe und deren derivate zur prävention und behandlung von herzkreislauf-, leber- und nierenerkrankungen und für kosmetische anwendungen
TNSN07148A1 (en) (biphenyl) carboxylic acids and derivatives thereof
UY26093A1 (es) Inhibidores de ap2 de bifenilos que contienen compuestos heterociclicos y metodo
BR9911043A (pt) Composição para o tratamento do hiv e outras infecções viróticas
BR9714634A (pt) Carbamatos de benzimidazola-2 para o tratamento de infecções viróticas de câncer
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
FI66722C (fi) Medel med germicid verkan foer vattensystem
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
KR910000631A (ko) 디-3급-부틸(히드록시)페닐 티오 치환된 히드록삼산 유도체
BR0316877A (pt) Derivados de aril-quinazolina/aril-2-amino-fenil metanona que promovem a liberação de hormÈnio da paratireóide
CO5231152A1 (es) Formulaciones plaguicidas que contienen tensoactivos de piliarilfenolfosfatoester alcoxilado y tensoactivo de lignosulfonato alcoxilado
KR950002588A (ko) 과산화수소 조성물
CO5160289A1 (es) Composicion farmaceutica que inhibe o detiene el crecimiento de viruses, en animales, particularmente mamiferos util para tratar infecciones virales
DE50210655D1 (de) Stabilisierung kosmetischer oder dermatologischer zubereitungen, welche repellent-wirkstoffe enthalten
ES2176719T3 (es) Derivados de benzopirano que tienen una accion antagonista de leucotrienos.
CA2412932A1 (en) Pleuromutilin derivatives having antibacterial activity
BRPI0405080A (pt) Método para purificação de ácido (met) acrìlico, produto de ácido (met) acrìlico, e, composição de polìmero
BR9611700A (pt) Uso de (tio)ésteres 1,2,3-tiadazolcaboxílicos para o controle de pragas
PE103799A1 (es) Procedimiento de purificacion de mesilato de alatrofloxacino
DE602007002794D1 (de) Behandlung von wässrigen flüssigkeiten und herstellung von anthranilsäure
CO5040149A1 (es) Un mercaptano latente como estabilizador de calor
CO5140099A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
ES2111938T3 (es) Composiciones para desodorizar heces animales y el correspondiente proceso desodorizante.
ATE332697T1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs